Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis

Gynecol Obstet Invest. 2001;52(4):217-22. doi: 10.1159/000052978.

Abstract

We performed a randomized controlled study to determine the efficacy of add-backed therapy by every-other-day administration of 0.625 mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) on GnRH agonists (GnRH-a) treatment in Japanese women with symptomatic endometriosis. At the end of treatment, serum estrone and estradiol levels in the add-back group (n = 11) were significantly higher than those in the control group (n = 10). The assessment of Beecham classification by bimanual examination, serum CA-125 levels, and the frequency of genital bleeding revealed no significant differences between the two groups. The add-back group showed reduced Kupperman indices relative to those of the control group, and could prevent the loss of bone density. These findings led to a conclusion that GnRH-a therapy added back by every-other-day administration of 0.625 mg CEE and 2.5 mg MPA was a safe and effective treatment for Japanese women with endometriosis.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Animals
  • Bone Density
  • Bone Remodeling
  • CA-125 Antigen / blood
  • Endometriosis / drug therapy*
  • Estradiol / blood
  • Estrogens, Conjugated (USP) / administration & dosage*
  • Estrone / blood
  • Female
  • Gonadotropin-Releasing Hormone / agonists*
  • Horses
  • Humans
  • Leuprolide / administration & dosage
  • Medroxyprogesterone Acetate / administration & dosage*
  • Middle Aged
  • Uterine Hemorrhage / epidemiology

Substances

  • CA-125 Antigen
  • Estrogens, Conjugated (USP)
  • Estrone
  • Gonadotropin-Releasing Hormone
  • Estradiol
  • Medroxyprogesterone Acetate
  • Leuprolide